Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Erdafitinib |
| Trade Name | Balversa |
| Synonyms | JNJ-42756493 |
| Drug Descriptions |
Balversa (erdafitinib) selectively inhibits FGFR1-4, resulting in decreased downstream signaling, and potentially leading to reduced growth of tumors with activated FGFR signaling (PMID: 28341788, PMID: 28965185). Balversa (erdafitinib) is FDA approved for use in patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations (FDA.gov). |
| DrugClasses | FGFR Inhibitor (Pan) 26 |
| CAS Registry Number | 1346242-81-6 |
| NCIT ID | C103273 |